Me-Too Cancer Drugs Not Often Compared to Original
The analysis of FDA-approved next-in-class drugs also found that, among RCTs with head-to-head trials, fewer than 1 in 4 of the me-too agents demonstrated a survival benefit.
Medscape Medical News
source https://www.medscape.com/viewarticle/me-too-cancer-drugs-not-often-compared-original-2025a1000kat?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/me-too-cancer-drugs-not-often-compared-original-2025a1000kat?src=rss
Comments
Post a Comment